FULLER H B CO — Form 8-K
Filed September 28, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 42/100
What the filing says
H.B. Fuller appointed R. Jeffrey Bailly to its Board of Directors effective immediately, replacing Ruth Kimmelshue who stepped down after 9 years. Bailly brings 30+ years of executive experience, including 31 years as CEO of UFP Technologies (1995–2026), where he led 20+ acquisitions and grew revenue ~20-fold and market cap 150-fold. The appointment supports H.B. Fuller's strategic pivot toward higher-margin medical end markets and its goal of >20% adjusted EBITDA margin.
Why this rating
Board refresh is routine governance; however, Bailly's M&A and medical-tech expertise directly supports stated transformation strategy. Modest positive signal but immaterial to $3B company valuation.
See more from September 28, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.